Vigabatrin-Induced Visual Field Defects

J Gordon Millichap

doi:10.15844/pedneurbriefs-12-2-7

Vigabatrin-Induced Visual Field Defects

Pediatric Neurology Briefs

Volume 12 (1998): Issue 2

By: J Gordon Millichap

Open Access

|Feb 1998

Abstract

A drug surveillance database at Hoechst Marion Roussel, manufacturers of vigabatrin, identified 92 cases of symptomatic visual field defects associated with vigabatrin (usually as add-on therapy) between 1990 and 1997.

References

Mackenzie R Klistorner A Severe persistent visual field constriction associated with vigabatrin. Asymptomatic as well as symptomatic defects occur with vigabatrin BMJ 1998 Jan 316 7126 232 233 10.1136/bmj.316.7126.232 9468717
Open DOI Search in Google Scholar Back to article
Harding GFA Benefit: risk ratio must be calculated for individual patients BMJ 1998 Jan 316 7126 232 233 10.1136/bmj.316.7126.232 9468716
Open DOI Search in Google Scholar Back to article

Articles in this issue

DOI: https://doi.org/10.15844/pedneurbriefs-12-2-7 | Journal eISSN: 2166-6482

Journal RSS Feed

Language: English

Page range: 12 - 13

Published on: Feb 1, 1998

Published by: Pediatric Neurology Briefs Publishers

In partnership with: Paradigm Publishing Services

Keywords:

Visual Field Defects,

Vigabatrin,

Carbamazepine

© 1998 J Gordon Millichap, published by Pediatric Neurology Briefs Publishers
This work is licensed under the Creative Commons Attribution 4.0 License.

Volume 12 (1998): Issue 2